A study presented at the annual meeting of the American Diabetes Association found that Takeda Pharmaceutical's TAK-875 drug fared better in reducing the risk of hypoglycemia in patients with type 2 diabetes compared to those in glimepiride and placebo treatments. It was just as effective as glimepiride in lowering hemoglobin A1c.

Related Summaries